CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Dolutegravir

Last Updated: October 18, 2013
Result type: Reports
Project Number: SR0357-000
Product Line: Reimbursement Review

Generic Name: Dolutegravir

Brand Name: Tivicay

Manufacturer: ViiV Healthcare ULC

Therapeutic Area: HIV infection

Indications: HIV infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 18, 2014

Recommendation Type: List